# BiomeBank

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biomebank

- Industry: Biotechnology
- Headquarters: Adelaide, Australia
- Website: www.biomebank.com
- Total disclosed funding: $7.3M
- Latest round: Series A (Dec 8, 2022)
- Investors on record: 2

## About

Based in Australia, and founded by Sam Costello (CEO), and Rob Bryant in 2018, COST-BRY Pty Ltd. doing business as BiomeBank is a clinical-stage biotechnology company developing microbial therapies to prevent disease by restoring gut microbial ecology. In December 2022, BiomeBank raised AUD 10.65 million in Series A funding from investors Artesian and Ellerston Capital.

The firm offers a microbiome-based therapy that can be administered to patients during enema or colonoscopy to help treat patients suffering from chronic diseases such as ulcerative colitis, Crohn’s disease, and irritable bowel syndrome. The product is encapsulated and freeze-dried for oral delivery and also offered as a syringe frozen for colonoscopy and enema delivery. 

The company intends to use the December 2022 funding for the discovery and development of second-generation cultured therapies.

## Funding rounds

- Series A, Dec 8, 2022, $7.3M — Ellerston Capital, Artesian

## Investors

- Ellerston Capital (https://capitalatlas.ai/funds/ellerston-capital) — Series A
- Artesian (https://capitalatlas.ai/funds/artesian) — Series A